VCAM1 and ovarian carcinoma: Since survival benefit is often dependent on lead time and preclinical detection rates, further studies are needed to validate the complementarity of serum VCAM-1 and CA-125 in detecting recurrent ovarian cancer and to examine the potential role of the identified biomarker panel for the early detection of ovarian cancer recurrence.